The Barcelona Science Park (PCB) has just scored another success story with the acquisition of one of the companies it has incubated in recent years, the deep tech Molomics Biotech. This startup joins the list of recent operations experienced at the PCB, such as those carried out by Infinitec Activos and Stat-Dx.
Molomics Biotech developed from the PCB facilities a technology that combines human collective intelligence with artificial intelligence for the design of new therapeutic molecules to treat, for example, Parkinson's disease. This combination reduces the number of uselessly tested molecules and represents savings of hundreds of millions of euros for the pharmaceutical industry.
The product created by the Barcelona-based company has been acquired, for an undisclosed amount, by the American VeriSIM Life, a global leader in artificial intelligence technologies for drug development. Molomics' technology will complement the American company's artificial intelligence platform, allowing for prior verification of new drugs in less time and at reduced costs, which will serve to increase the success rate.
Founded in 2015 by Jascha Blobel (CEO), Giovanni Cincilla (CSO) and Simone Masoni (CTO), the company left the PCB a few months ago. It did so with the aim of reducing costs and focusing on finding a buyer, after failing to close a large funding round, says its CEO. After the acquisition, the three founders will go their separate ways.
Most of the company's capital was held by the founding team. Under the transaction, the vast majority of shareholders will also receive shares in VeriSIM Life, which raised some 14.4 million euros in a Series A round in January of this year.
Since its inception, Molomics has raised more than one million euros in public and private capital. The startup has received financial support from the Ministry of Science and Innovation, as well as backing from the Michael J. Fox Foundation in its projects aimed at Parkinson's disease.
Add The New Barcelona Post as your preferred Google source for free
Stay informed with the latest news.
